Results 1 to 10 of about 1,669,323 (263)

Hepatocellular carcinoma [PDF]

open access: yesNature Reviews Disease Primers, 2021
Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepatitis C virus are the main risk factors for HCC development, although non-alcoholic steatohepatitis ...
Llovet, Josep M.   +9 more
semanticscholar   +5 more sources

Case Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy. [PDF]

open access: yesFront Immunol
IntroductionHepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with most patients diagnosed at advanced stages, often precluding surgical resection.
Fang Q   +7 more
europepmc   +2 more sources

Hepatocellular Carcinoma [PDF]

open access: yesCurrent Opinion in Oncology, 2000
Hepatocellular carcinoma (HCC) is a disease that is extremely difficult to manage and is increasing markedly in incidence. This presents both an opportunity and a challenge. At-risk patients can be identified and early detection of HCC is feasible. New surgical techniques and postoperative therapies, including hepatic intra-arterial radiation, may ...
LENCIONI, RICCARDO ANTONIO   +2 more
  +16 more sources

Hepatocellular carcinoma [PDF]

open access: yesCurrent Opinion in Gastroenterology, 2001
The number of papers published regarding hepatocellular carcinoma between 1999 and 2001 increased from previous years. This year a study confirmed the increase in incidence in the United States. Also, several studies established for the first time that tobacco smoking was a risk factor for the development of this tumor. Several studies established that
M M, Chokshi, J A, Marrero
openaire   +4 more sources

CD58 acts as a tumor promotor in hepatocellular carcinoma via activating the AKT/GSK-3β/β-catenin pathway

open access: yesJournal of Translational Medicine, 2023
Background Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide because of rapid progression and high incidence of metastasis or recurrence.
Chuanzheng Wang   +7 more
doaj   +1 more source

Resveratrol protects against chronic alcohol-induced liver disease in a rat model

open access: yesSTEMedicine, 2022
Hepatic ethanol metabolism participates in the pathogenesis of alcoholic liver disease (ALD). We aimed to evaluate the protecting effects and underlying mechanisms of Resveratrol against ALD.
Hanzhang Zhu   +3 more
doaj   +1 more source

AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

open access: yesHepatology, 2023
for End-Stage Liver Disease;
A. Singal   +15 more
semanticscholar   +1 more source

Hepatocellular carcinoma [PDF]

open access: yesAnales del Sistema Sanitario de Navarra, 2016
Liver cancer is the second leading cause of cancer-related deaths globally and has an incidence of approximately 850,000 new cases per year. Hepatocellular carcinoma (HCC) represents approximately 90% of all cases of primary liver cancer. The main risk factors for developing HCC are well known and include hepatitis B and C virus infection, alcohol ...
Llovet, Josep M.   +6 more
  +9 more sources

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

open access: yesNew England Journal of Medicine, 2020
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
R. Finn   +20 more
semanticscholar   +1 more source

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

open access: yesNEJM Evidence, 2022
Tremelimumab/Durvalumab for Hepatocellular CarcinomaThis trial examined overall survival (OS) with tremelimumab plus durvalumab, durvalumab alone, or sorafenib in untreated patients with hepatocellular cancer who were not candidates for locoregional ...
G. Abou-Alfa   +30 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy